会員登録
ログイン
【4578】大塚ホールディングス
製薬。抗精神病。機能性食品『ポカリスエット』など。
売上高
営業利益
経常利益
当期利益
業績予想修正
対前回修正率
当初予想比較
| 決算期 | 日付 | 予・実 | 売上高 (百万円) | 対前回 | 営業利益 (百万円) | 対前回 | 経常利益 (百万円) | 対前回 | 当期利益 (百万円) | 対前回 |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025.12 | 2025/02/14 | 当初予 | 2,380,000 | - | 375,000 | - | - | - | 275,000 | - |
| 2024.12 | 2025/02/14 | 実 | 2,329,861 | ↑ | 323,564 | ↓ | - | - | 343,120 | ↑ |
| 2024.12 | 2025/02/07 | 修正予 | 2,320,000 | ↑ | 335,000 | ↑ | 335,000 | - | 343,000 | ↑ |
| 2024.12 | 2024/10/31 | Q3予 | 2,310,000 | ↓ | 320,000 | ↑ | - | - | 240,000 | → |
| 2024.12 | 2024/08/01 | Q2予 | 2,315,000 | ↑ | 302,000 | ↓ | - | - | 240,000 | ↓ |
| 2024.12 | 2024/04/30 | Q1予 | 2,140,000 | → | 330,000 | → | - | - | 250,000 | → |
| 2024.12 | 2024/02/14 | 当初予 | 2,140,000 | - | 330,000 | - | - | - | 250,000 | - |
| 2023.12 | 2024/02/14 | 実 | 2,018,568 | ↑ | 139,612 | ↑ | - | - | 121,616 | ↑ |
| 2023.12 | 2024/02/13 | 修正予 | 2,018,000 | ↑ | 139,000 | ↓ | 142,000 | - | 121,000 | ↓ |
| 2023.12 | 2023/10/31 | Q3予 | 1,985,000 | ↑ | 245,000 | → | - | - | 188,000 | → |
| 2023.12 | 2023/07/31 | Q2予 | 1,905,000 | ↑ | 245,000 | ↑ | - | - | 188,000 | ↑ |
| 2023.12 | 2023/05/12 | Q1予 | 1,800,000 | → | 210,000 | → | - | - | 157,500 | → |
| 2023.12 | 2023/02/14 | 当初予 | 1,800,000 | - | 210,000 | - | - | - | 157,500 | - |
| 2022.12 | 2023/02/14 | 実 | 1,737,998 | ↑ | 150,323 | ↑ | - | - | 134,019 | ↑ |
| 2022.12 | 2022/10/31 | Q3予 | 1,710,000 | ↑ | 142,000 | ↓ | - | - | 131,000 | ↓ |
| 2022.12 | 2022/07/29 | Q2予 | 1,670,000 | ↑ | 152,000 | ↓ | - | - | 135,000 | ↓ |
| 2022.12 | 2022/02/10 | 当初予 | 1,550,000 | - | 192,000 | - | - | - | 146,000 | - |
| 2021.12 | 2022/02/10 | 実 | 1,498,276 | ↑ | 154,497 | ↓ | - | - | 125,463 | ↑ |
| 2021.12 | 2022/01/27 | 修正予 | 1,498,000 | ↑ | 163,000 | ↓ | 163,000 | - | 125,000 | ↓ |
| 2021.12 | 2021/11/12 | Q3予 | 1,480,000 | → | 203,000 | ↓ | - | - | 161,000 | ↓ |
| 2021.12 | 2021/08/06 | Q2予 | 1,480,000 | ↑ | 208,000 | ↑ | - | - | 165,000 | ↑ |
| 2021.12 | 2021/05/13 | Q1予 | 1,423,000 | → | 192,000 | → | - | - | 146,000 | → |
| 2021.12 | 2021/02/12 | 当初予 | 1,423,000 | - | 192,000 | - | - | - | 146,000 | - |
| 2020.12 | 2021/02/12 | 実 | 1,422,826 | ↑ | 198,582 | ↓ | - | - | 148,137 | ↓ |
| 2020.12 | 2020/11/13 | Q3予 | 1,420,000 | ↑ | 203,000 | ↑ | 195,000 | ↓ | 150,000 | → |
| 2020.12 | 2020/08/07 | Q2予 | 1,410,000 | ↓ | 202,000 | ↑ | 200,000 | ↑ | 150,000 | ↑ |
| 2020.12 | 2020/05/28 | Q1予 | 1,445,000 | → | 197,000 | → | 195,000 | → | 145,000 | → |
| 2020.12 | 2020/02/14 | 当初予 | 1,445,000 | - | 197,000 | - | 195,000 | - | 145,000 | - |
| 2019.12 | 2020/02/14 | 実 | 1,396,240 | ↓ | 176,585 | ↑ | 173,515 | ↑ | 127,151 | ↑ |
| 2019.12 | 2019/11/12 | Q3予 | 1,400,000 | → | 174,000 | → | 170,000 | → | 125,000 | → |
| 2019.12 | 2019/08/08 | Q2予 | 1,400,000 | ↑ | 174,000 | ↑ | 170,000 | ↑ | 125,000 | ↑ |
| 2019.12 | 2019/05/14 | Q1予 | 1,390,000 | → | 150,000 | → | 147,500 | → | 110,000 | → |
| 2019.12 | 2019/02/13 | 当初予 | 1,390,000 | - | 150,000 | - | 147,500 | - | 110,000 | - |
| 2018.12 | 2019/02/13 | 実 | 1,291,981 | ↑ | 108,304 | ↓ | 109,497 | ↓ | 82,492 | ↓ |
| 2018.12 | 2018/11/14 | Q3予 | 1,290,000 | ↓ | 127,000 | ↓ | 128,000 | ↓ | 100,000 | ↓ |
| 2018.12 | 2018/08/08 | Q2予 | 1,300,000 | → | 145,000 | ↑ | 147,000 | ↑ | 115,000 | ↑ |
| 2018.12 | 2018/05/11 | Q1予 | 1,300,000 | → | 140,000 | → | 137,000 | → | 105,000 | → |
| 2018.12 | 2018/02/14 | 当初予 | 1,300,000 | - | 140,000 | - | 137,000 | - | 105,000 | - |
| 2017.12 | 2018/02/14 | 実 | 1,239,952 | ↓ | 104,181 | ↑ | 103,712 | ↑ | 112,492 | ↑ |
| 2017.12 | 2018/02/08 | 修正予 | 1,240,000 | ↓ | 104,000 | ↓ | 103,000 | ↓ | 112,000 | ↑ |
| 2017.12 | 2017/11/14 | Q3予 | 1,260,000 | → | 120,000 | → | 119,000 | → | 85,000 | → |
| 2017.12 | 2017/08/08 | Q2予 | 1,260,000 | → | 120,000 | → | 119,000 | → | 85,000 | → |
| 2017.12 | 2017/05/12 | Q1予 | 1,260,000 | → | 120,000 | → | 119,000 | → | 85,000 | → |
| 2017.12 | 2017/02/14 | 当初予 | 1,260,000 | - | 120,000 | - | 119,000 | - | 85,000 | - |
| 2016.12 | 2017/02/14 | 実 | 1,195,547 | ↓ | 101,145 | ↓ | 116,680 | ↑ | 92,563 | ↑ |
| 2016.12 | 2016/11/11 | Q3予 | 1,200,000 | ↓ | 115,000 | ↑ | 115,000 | ↑ | 85,000 | ↑ |
| 2016.12 | 2016/05/13 | Q1予 | 1,250,000 | → | 70,000 | → | 80,000 | → | 50,000 | → |
| 2016.12 | 2016/02/12 | 当初予 | 1,250,000 | - | 70,000 | - | 80,000 | - | 50,000 | - |
| 2015.12 | 2016/02/12 | 実 | 1,445,227 | ↑ | 151,837 | ↑ | 159,899 | ↑ | 84,086 | ↓ |
| 2015.12 | 2015/11/13 | Q3予 | 1,410,000 | ↑ | 145,000 | ↑ | 150,000 | ↑ | 90,000 | ↑ |
| 2015.12 | 2015/08/07 | Q2予 | 1,380,000 | ↑ | 120,000 | ↑ | 125,000 | ↑ | 80,000 | → |
| 2015.12 | 2015/05/13 | Q1予 | 1,370,000 | → | 110,000 | → | 120,000 | → | 80,000 | → |
| 2015.12 | 2015/02/13 | 当初予 | 1,370,000 | - | 110,000 | - | 120,000 | - | 80,000 | - |
| 2014.12 | 2015/02/13 | 実 | 1,224,298 | ↑ | 196,528 | ↑ | 217,210 | ↑ | 143,143 | ↑ |
| 2014.12 | 2014/11/13 | Q2予 | 1,200,000 | → | 190,000 | → | 195,000 | → | 130,000 | → |
| 2014.12 | 2014/08/08 | Q1予 | 1,200,000 | → | 190,000 | → | 195,000 | → | 130,000 | → |
| 2014.12 | 2014/05/14 | 当初予 | 1,200,000 | - | 190,000 | - | 195,000 | - | 130,000 | - |
| 2014.03 | 2014/05/14 | 実 | 1,452,759 | - | 198,702 | - | 215,235 | - | 150,989 | - |
